bDMARDs Quick Reference Guide
Severe chronic plaque psoriasis
Severe psoriatic arthritis
None
Pre-filled syringe 100mg/mL
Pre-filled pen 100mg/mL
Instructions for patient self-administration are included with the product.
Store at 2-8oC (refrigerate do not freeze).
Keep pre-filled syringes in the outer carton until time of use to protect from light.
Before use, remove the carton from the refrigerator and keep the pre-filled syringe inside the carton and allow to reach room temperature by waiting for 30 minutes.
Plaque psoriasis and psoriatic arthritis: 100mg at week 0, week 4 and every 8 weeks thereafter.
Treatment with csDMARDs (e.g., methotrexate) can continue whilst the patient is on guselkumab.
Guselkumab has the potential to reactivate latent TB (begin TB treatment before starting).
Patients with suspected latent or active TB should be treated in consultation with an Infectious Diseases physician.
Guselkumab may increase the risk of infection. Treatment should not be initiated in patients with clinically significant active infection until the infection resolves or is adequately treated.
Live vaccines should not be given concurrently with guselkumab or for at least 3 months after cessation of therapy.
Pharmaceutical benefits Scheme (PBS) listing. Available from https://www.pbs.gov.au/medicine/item/11614G [accessed 8/10/21]
Product information. Available from https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2018-PI-01506-1 [accessed 8/10/21]
Australian Medicines Handbook 2020 (online). Adelaide: Australian Medicines Handbook Pty Ltd; 2020 July. Available from: https://amhonline.amh.net.au/